NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Short Interest Up 92.7% in January

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) was the target of a large increase in short interest in January. As of January 15th, there was short interest totaling 3,527,843 shares, an increase of 92.7% from the December 31st total of 1,831,090 shares. Approximately 14.7% of the shares of the company are sold short. Based on an average daily trading volume, of 2,710,433 shares, the short-interest ratio is currently 1.3 days. Based on an average daily trading volume, of 2,710,433 shares, the short-interest ratio is currently 1.3 days. Approximately 14.7% of the shares of the company are sold short.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on the company. Zacks Research cut NRx Pharmaceuticals from a “hold” rating to a “strong sell” rating in a report on Monday, January 26th. BTIG Research reissued a “buy” rating and set a $25.00 price objective on shares of NRx Pharmaceuticals in a research note on Thursday, January 15th. Wall Street Zen upgraded shares of NRx Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Sunday, November 23rd. HC Wainwright reiterated a “buy” rating on shares of NRx Pharmaceuticals in a report on Wednesday, January 21st. Finally, Ascendiant Capital Markets reissued a “buy” rating and issued a $48.00 target price (up previously from $47.00) on shares of NRx Pharmaceuticals in a research report on Friday, January 2nd. Four analysts have rated the stock with a Buy rating and two have issued a Sell rating to the company. According to MarketBeat.com, NRx Pharmaceuticals has an average rating of “Hold” and a consensus price target of $36.75.

NRx Pharmaceuticals Stock Performance

Shares of NRXP stock traded down $0.02 during mid-day trading on Friday, hitting $2.10. 379,991 shares of the stock traded hands, compared to its average volume of 1,785,069. The company’s 50-day simple moving average is $2.31 and its 200-day simple moving average is $2.66. NRx Pharmaceuticals has a twelve month low of $1.58 and a twelve month high of $3.84. The firm has a market cap of $62.17 million, a price-to-earnings ratio of -0.89 and a beta of 1.62.

NRx Pharmaceuticals (NASDAQ:NRXP) last posted its quarterly earnings results on Friday, November 14th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.07). The business had revenue of $0.24 million for the quarter, compared to analysts’ expectations of $6.83 million. Analysts forecast that NRx Pharmaceuticals will post -1.75 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Geode Capital Management LLC increased its stake in shares of NRx Pharmaceuticals by 27.9% during the 2nd quarter. Geode Capital Management LLC now owns 172,255 shares of the company’s stock worth $562,000 after purchasing an additional 37,598 shares during the last quarter. Ethos Financial Group LLC acquired a new position in shares of NRx Pharmaceuticals in the 3rd quarter valued at $39,000. One Wealth Management Investment & Advisory Services LLC raised its holdings in shares of NRx Pharmaceuticals by 86.1% in the 3rd quarter. One Wealth Management Investment & Advisory Services LLC now owns 27,991 shares of the company’s stock worth $92,000 after buying an additional 12,950 shares in the last quarter. AdvisorShares Investments LLC increased its position in shares of NRx Pharmaceuticals by 29.7% during the 3rd quarter. AdvisorShares Investments LLC now owns 342,136 shares of the company’s stock worth $1,129,000 after purchasing an additional 78,339 shares in the last quarter. Finally, Vanguard Group Inc. increased its holdings in NRx Pharmaceuticals by 18.3% during the 3rd quarter. Vanguard Group Inc. now owns 534,956 shares of the company’s stock valued at $1,765,000 after purchasing an additional 82,781 shares in the last quarter. 4.27% of the stock is owned by institutional investors and hedge funds.

NRx Pharmaceuticals Company Profile

NRx Pharmaceuticals, Inc is a clinical-stage specialty biopharmaceutical company focused on the development and repurposing of small-molecule therapeutics for central nervous system and rare disease indications. The company’s research strategy centers on advancing compounds with established safety profiles into new neurological and inflammatory conditions, leveraging translational science and biomarker-driven trial design to accelerate clinical development. NRx’s pipeline includes Ifenprodil, an NMDA receptor antagonist in investigation for acute respiratory distress syndrome and inflammatory muscle disorders, as well as investigational formulations targeting depressive and cognitive disorders.

Since securing global rights to its lead assets, NRx has initiated multiple proof-of-concept studies in the United States and Europe, collaborating with academic institutions and clinical research organizations to evaluate safety and efficacy across a range of indications.